Notice NOT-NS-21-053 from the NIH Guide for Grants and Contracts

Notice NOT-AG-21-021 from the NIH Guide for Grants and Contracts

Notice NOT-NS-21-054 from the NIH Guide for Grants and Contracts

Notice NOT-OD-21-091 from the NIH Guide for Grants and Contracts

Notice NOT-OD-21-089 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-CA-21-025 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is a part of the NCI, Division of Cancer Treatment and Diagnosis (DCTD), Office of Cancer Clinical Proteomics Research (OCCPR), Clinical Proteomic Tumor Analysis Consortium (CPTAC) program. This reissuance of the CPTAC program leverages recent advancements in cancer proteomics and genomics to better understand the complexity between the proteome and the genome in cancer and accelerate research in these areas by disseminating research resources for the scientific community. The program will continue to 1) support an increased understanding of cancer through comprehensive proteogenomic approaches, 2) expand support for the development of novel cancer diagnostics and therapeutics by implementing proteogenomic strategies to understand drug response and development of resistance in the context of a clinical trial, and 3) accelerate its translation through public resources (such as data, assays, images and reagents) that catalyze hypothesis-driven science.

Funding Opportunity RFA-CA-21-024 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports the NCI Clinical Proteomic Tumor Analysis Consortium (CPTAC) managed by the Office of Cancer Clinical Proteomics Research (OCCPR). CPTAC leverages recent advancements in cancer proteomics and genomics to better understand the complexity between the proteome and the genome in cancer and accelerate research in these areas by disseminating resources for the scientific community. The program will continue to 1) support an increased understanding of cancer through comprehensive proteogenomic approaches, 2) expand support for the development of novel cancer diagnostics and therapeutics by implementing proteogenomic strategies to understand drug response and development of resistance in the context of a clinical trial, and 3) accelerate its translation through public resources (such as data, assays, images and reagents) that catalyze hypothesis-driven science.

Funding Opportunity RFA-CA-21-023 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports the NCI Clinical Proteomic Tumor Analysis Consortium (CPTAC) managed by theOffice of Cancer Clinical Proteomics Research (OCCPR). CPTAC leverages recent advancements in cancer proteomics and genomics to better understand the complexity between the proteome and the genome in cancer and accelerate research in these areas by disseminating research resources for the scientific community. The program will continue to 1) support an increased understanding of cancer through comprehensive proteogenomic approaches, 2) expand support for the development of novel cancer diagnostics and therapeutics by implementing proteogenomic strategies to understand drug response and development of resistance in the context of a clinical trial, and 3) accelerate its translation through public resources (such as data, assays, images, and reagents) that catalyze hypothesis-driven science.

Funding Opportunity PAR-21-181 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) is issued by the National Institute of Neurological Disorders and Stroke to enable submission of program project grant applications that propose to conduct innovative, interactive research to answer significant scientific questions that are important for the mission of NINDS, via a synergistic collaboration between outstanding scientists who might not otherwise collaborate. The program project grant is designed to support research in which the funding of several interdependent highly meritorious projects as a group offers significant scientific advantages over support of these same projects as individual research grants.

Funding Opportunity RFA-NS-21-014 from the NIH Guide for Grants and Contracts. (Reissue of RFA-NS-18-014) This R34 FOA solicits applications that offer a limited scope of aims and an approach that will establish feasibility, validity, or other technically qualifying results that, if successful, would support, enable, and/or lay the groundwork for a potential, subsequent Targeted Brain Circuits Projects - TargetedBCP R01, as described in the companion FOA (RFA-NS-18-009). Applications should be exploratory research projects that use innovative, methodologically-integrated approaches to understand how circuit activity gives rise to mental experience and behavior.

Funding Opportunity RFA-NS-21-013 from the NIH Guide for Grants and Contracts. (Reissue of RFA-NS-18-030) This FOA solicits applications for research projects that use innovative, methodologically-integrated approaches to understand how circuit activity gives rise to mental experience and behavior. The goal is to support projects that can realize a meaningful outcome within 5 years. Applications should address circuit function in the context of specific neural systems such as sensation, perception, attention, reasoning, intention, decision-making, emotion, navigation, communication or homeostasis. Projects should link theory and data analysis to experimental design and should produce predictive models as deliverables. Projects should aim to improve the understanding of circuits of the central nervous system by systematically controlling stimuli and/or behavior while actively recording and/or manipulating dynamic patterns of neural activity. Projects can use non-human and human species, and applications should explain how the selected species offers ideal conditions for revealing general principles about the circuit basis of a specific behavior.

Funding Opportunity RFA-AA-21-006 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for Comprehensive Alcohol Research Centers using the P60 mechanism which requires a dissemination core to initiate and expand community education related to the activities of the center. The overall purpose of the NIAAA Alcohol Research Center program is to provide leadership in conducting and fostering interdisciplinary, collaborative research on a wide variety of topics relevant to the Institutes mission. These topics include, but are not limited to: the nature, etiology, genetics, diagnosis, treatment, and prevention of alcohol use disorder, alcohol-related end organ diseases and their biomedical, psychosocial, and economic consequences across the lifespan and racial/ethnic groups and other health disparity populations. Centers also are regional or national resources that contribute to the development of new research methods, technologies and approaches that sustain innovative goal-directed research.

Funding Opportunity RFA-AA-21-005 from the NIH Guide for Grants and Contracts. The overarching goal of the National Institute on Alcohol Abuse and Alcoholism (NIAAA) is to support a broad-based Alcohol Research Centers program to foster and conduct interdisciplinary, collaborative research on alcoholism, alcohol use disorder and the impact of alcohol on health and disease.

Funding Opportunity RFA-TR-21-015 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to promote partnerships between intramural investigators at the NCATS 3-D Bioprinting Laboratory and extramural researchers to jointly develop and demonstrate the use of 3-D biofabricated tissues for disease modeling and drug screening.

Notice NOT-AR-21-021 from the NIH Guide for Grants and Contracts

Notice NOT-MH-21-255 from the NIH Guide for Grants and Contracts

Notice NOT-MH-21-250 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-AI-21-019 from the NIH Guide for Grants and Contracts. Research funded by this initiative will examine the effects of radiation exposure on the immune system and explore possible treatments for radiation-induced immune dysfunction. Research gaps exist in understanding the mechanisms of injury and repair with regard to radiation-induced immune system dysfunction, and these gaps must be addressed to better develop MCMs for radiation exposure. Through this initiative, the NIAID Radiation and Nuclear Countermeasures Program (RNCP) will support development of animal models for immune-targeted radiation injuries, studies to better understand radiation impacts on the immune system (including immune system-mediated multi-organ injury), identification of immune-specific pathways targeted by radiation, as well as biomarkers of exposure and mitigators/treatments that target immune-related radiation response pathways.

Funding Opportunity RFA-DA-22-002 from the NIH Guide for Grants and Contracts. The National Institute on Drug Abuse (NIDA) supports a program of longitudinal cohorts to address emerging and high priority research on HIV/AIDS in the context of injection and non-injection substance abuse. These cohorts provide a strong resource platform for current and future collaborative efforts with other investigators to address emerging questions related to HIV pathogenesis, prevention, and treatment in the context of substance abuse, as well as to foster the creativity and efficiency of investigatorinitiated research projects. The diverse research activities among these cohorts include basic immunologic, and virologic studies, as well as studies on HIV prevention and treatment, and the co-morbidities and co-infections associated with HIV and substance abuse. NIDA has determined that a coordinating center (CC) is needed in order to take advantage of these rich sources of data and bio-specimens and optimize collaborations among both the cohort investigators and other researchers not funded under the cohort program. In addition, the CC is expected to establish a virtual repository, and facilitate the leadership of the cohorts steering committee (SC), consisting of representatives from the NIDA-funded cohorts and NIDA staff.

Notice NOT-NS-21-052 from the NIH Guide for Grants and Contracts